Abstract
Antimicrobial-resistant pathogens are becoming increasingly prevalent in diabetic foot infections. The oxazolidinones are a new synthetic class of antibiotics that inhibit bacterial protein synthesis. Linezolid has a wide spectrum of activity against Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus, and is the first oxazolidinone antibiotic approved for use in the management of diabetic foot infections. It has been shown to be as effective as an aminopenicillin and β-lactamase inhibitor regimen in all types of diabetic foot infections. Linezolid has an oral formulation that allows for an initiation of oral out-patient therapy, or a step-down from intravenous to oral therapy. The decreased duration of hospital stays observed in some studies associated with the use of oral linezolid suggests the possibility for potential cost savings and optimization of resource utilization in the management of moderate or severe diabetic foot infections.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
